Compare Bristol-Myers Squibb Co (BMY) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Twilio Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Twilio Inc trades at $219.99 (market cap $33.06B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.5× Twilio Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| BMY | TWLO | |
|---|---|---|
Market Cap | $116.30B | $33.06B |
Sector | Health | Technology |
52-Week High | $62.37 | $236.64 |
52-Week Low | $42.60 | $92.44 |
Enterprise Value | $152.24B | $31.78B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Twilio (TWLO) trades at $218.24, up 1.72% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $212 and resistance at $223. Revenue grew to $5.07B in 2025, with net income turning positive at $33.83M, signaling a successful turnaround. Analyst sentiment is overwhelmingly positive, with 77% recommending Buy and a consensus price target of $215.14. Operating cash flow reached $1.0B, reflecting improved financial health.
Outlook: Twilio's AI-driven communication tools and margin expansion under CEO Khozema Shipchandler support growth, but high valuation multiples (P/E 330.67) pose risks. Competition and execution challenges remain key concerns. The stock offers upside if earnings momentum continues, yet volatility near 52-week highs warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
